7 products under Gate have successfully obtained production licenses.

On September 5, 2025, Gate Pharmaceutical Division announced that it has successfully obtained 7 drug production registration approvals issued by the National Medical Products Administration of China. This significant progress marks Gate's continued innovation and development in the pharmaceutical field.

Diversified Drug Portfolio Demonstrates R&D Strength

The approved drugs cover multiple therapeutic areas, demonstrating Gate's extensive capabilities in pharmaceutical research and development:

1. Arginine Perindopril Tablets: As the second company approved in the country, Gate's hypertension and heart failure treatment drug demonstrates its competitiveness in the cardiovascular field.

2. Progesterone Injection: This product is mainly used in assisted reproductive technology, reflecting Gate's layout in the field of reproductive health.

3. Labetalol Hydrochloride Injection: The approval of this multifunctional antihypertensive drug further solidifies Gate's position in the treatment of hypertension.

4. Calcium Chloride Injection: As an emergency medication, it demonstrates Gate's emphasis on medication for critical situations.

5. Compound Electrolyte Sodium Acetate Injection: The approval of this product reflects Gate's expertise in supplementing electrolytes and regulating acid-base balance.

6. Compound electrolyte injection: The approval of this product further enriches Gate's infusion product line.

7. Levosalbutamol hydrochloride aerosol inhalation solution: The approval of this product includes not only the formulation but also the active pharmaceutical ingredient, demonstrating Gate's comprehensive layout in the respiratory medication field.

Quality Assurance and Innovation Equally Important

It is worth noting that these approved drugs all belong to Class 3 or Class 4 chemical drugs and are considered to have passed the consistency evaluation. This not only reflects Gate's high emphasis on product quality but also highlights its innovation capabilities in the generic drug field.

The future development prospects are broad.

With the approval of these 7 drugs, Gate's competitiveness in the Chinese pharmaceutical market will be further enhanced. These products cover several important areas, including cardiovascular, reproductive health, emergency medicine, electrolyte balance, and respiratory system, laying a solid foundation for Gate's continued development in the pharmaceutical industry in the future.

Gate's successful approval this time not only demonstrates its strength in pharmaceutical research and production but also reflects the company's strategic vision in meeting diverse medical needs. As these new drugs gradually enter the market, they are expected to bring considerable economic benefits to Gate, while also providing patients with more high-quality treatment options.